Article
Medicine, General & Internal
Hun-Ju Yu, Meng-Ni Chuang, Chiao-Lun Chu, Pei-Lin Wu, Shu-Chen Ho, Ho-Chang Kuo
Summary: Kawasaki disease (KD) is a systemic vasculitis that primarily affects children under the age of 5, with significant complications such as coronary artery lesions. Recent studies have shown an increasing incidence of myopia among KD patients, indicating that IVIG treatment may decrease the risk of myopia in this population.
JOURNAL OF CLINICAL MEDICINE
(2021)
Article
Immunology
Nana Wang, Zhongyue Chen, Fan Zhang, Qianwen Zhang, Ling Sun, Haitao Lv, Bo Wang, Jie Shen, Xufang Zhou, Feiyan Chen, Binwei Zhang, Lijun Meng, Huiting Zhou, ZhenJiang Bai, Jie Huang
Summary: This study found that the quantity and phenotypes of immune cells were altered in patients with Kawasaki disease, and intravenous immunoglobulin therapy could restore these changes. These findings are important for understanding the immunomodulatory actions of intravenous immunoglobulin in the treatment of Kawasaki disease.
FRONTIERS IN IMMUNOLOGY
(2022)
Article
Pediatrics
Yaheng Lu, Tingting Chen, Yizhou Wen, Feifei Si, Xindan Wu, Yanfeng Yang
Summary: This study found that predictors PCT and CRP can be used to predict resistance to repeated IVIG treatment in patients with Kawasaki disease.
Article
Cardiac & Cardiovascular Systems
Xiaoliang Liu, Lin Wang, Shuran Shao, Nanjun Zhang, Mei Wu, Lei Liu, Yimin Hua, Kaiyu Zhou, Li Yu, Hua Wang, Chuan Wang
Summary: The incidence of sterile pyuria is relatively low in KD patients. Patients with sterile pyuria in KD exhibited a more severe inflammatory burden and were more likely to develop the initial IVIG resistance and moderate/giant CAAs. The overall prognosis of KD patients with sterile pyuria was satisfactory.
FRONTIERS IN CARDIOVASCULAR MEDICINE
(2022)
Review
Medicine, General & Internal
Pallavi L. Nadig, Vibhu Joshi, Rakesh Kumar Pilania, Rajni Kumrah, Jayakanthan Kabeerdoss, Saniya Sharma, Deepti Suri, Amit Rawat, Surjit Singh
Summary: Kawasaki disease (KD) is a childhood vasculitis that primarily affects medium vessels, particularly the coronary arteries. Coronary artery aneurysm occurs in about 25-30% of untreated cases, leading to significant morbidity. Intravenous immunoglobulin (IVIg) has been consistently shown to reduce the risk of coronary artery aneurysms to less than 5%, but the mechanism of immunomodulation is still unclear. Studies suggest that IVIg may modulate the innate immune system by affecting toll-like receptor pathways, autophagy, apoptosis, neutrophil extracellular trap, dendritic cell modulation, T-cell differentiation, cytokine release, and regulatory T-cell function. This review discusses the potential mechanisms underlying the immunomodulatory actions of IVIg in KD patients and summarizes the evidence regarding infusion protocols and dosages used in treatment.
Article
Immunology
Xueli Hu, Ru Fan, Wenzhu Song, Jianbo Qing, Xiaoyan Yan, Yaheng Li, Qi Duan, Yafeng Li
Summary: By screening and analyzing the differential intestinal flora between the three disease groups of IgAN, Kawasaki disease, and IgA vasculitis and their healthy controls, common differential flora were found, which may provide new insights into the pathogenesis of these three diseases.
FRONTIERS IN CELLULAR AND INFECTION MICROBIOLOGY
(2022)
Article
Endocrinology & Metabolism
Shuran Shao, Kaiyu Zhou, Xiaoliang Liu, Lei Liu, Mei Wu, Yuxin Deng, Hongyu Duan, Yifei Li, Yimin Hua, Chuan Wang
Summary: This study found that lipid profiles were significantly dysregulated in KD patients with IVIG resistance and CALs. Some of them, such as LDL-C and Apo A, could serve as complementary laboratory markers for predicting both IVIG resistance and CALs.
JOURNAL OF CLINICAL ENDOCRINOLOGY & METABOLISM
(2021)
Article
Medicine, Research & Experimental
Fengchuan Jing, Haobo Weng, Qiongfei Pei, Jing Zhang, Ruixi Liu, Qijian Yi
Summary: miR-221-3p may be involved in the pathogenesis of KD and IVIG resistance, and miR-221-3p can be used as a new potential biomarker to predict IVIG resistance in children with KD.
CLINICAL AND EXPERIMENTAL MEDICINE
(2022)
Article
Pediatrics
Nobuaki Michihata, Takanori Suzuki, Tetsushi Yoshikawa, Kazuyoshi Saito, Hiroki Matsui, Kiyohide Fushimi, Hideo Yasunaga
Summary: This study analyzed a national inpatient database to determine the appropriate dosage of intravenous immunoglobulin (IVIG) for preventing coronary artery abnormalities (CAAs) in patients with acute Kawasaki disease (KD). It found a U-shaped association between IVIG dose and the proportion of CAAs, with the optimal dosage being 2 g/kg.
EUROPEAN JOURNAL OF PEDIATRICS
(2022)
Article
Biochemistry & Molecular Biology
Yusuke Motoji, Ryuji Fukazawa, Ryosuke Matsui, Noriko Nagi-Miura, Yasuo Miyagi, Yasuhiko Itoh, Yosuke Ishii
Summary: This study found that Kawasaki disease may promote the development of atherosclerosis in adulthood. Long-term treatment with HMG-CoA inhibitors (statins) effectively suppressed the occurrence of atherosclerosis and inflammatory cell infiltration. Therefore, statin treatment may be used for secondary prevention of cardiovascular events during the chronic phase of Kawasaki disease.
Article
Biochemistry & Molecular Biology
Xiaoliang Liu, Tingting Luo, Zhenxin Fan, Jiawen Li, Yue Zhang, Guoyan Lu, Mingyi Lv, Sha Lin, Ziwen Cai, Jinbao Zhang, Kaiyu Zhou, Junling Guo, Yimin Hua, Yaoyao Zhang, Yifei Li
Summary: This study used single-cell RNA sequencing to explore the molecular mechanisms of immune responses in vasculitis in both Kawasaki disease (KD) and COVID-19, and validated the results through in vitro experiments. The findings showed that the immune cell compositions were altered in both KD and COVID-19, with an elevated ratio of CD14+ monocytes. CD14+ monocytes were found to play an important role in the immune response. Different types of B cells were involved in both KD and COVID-19, while only T cells were activated in KD.
BIOCHIMICA ET BIOPHYSICA ACTA-MOLECULAR BASIS OF DISEASE
(2023)
Article
Immunology
Xi Chen, Lu Gao, Zhen Zhen, Ying Wang, Jia Na, Wen Yu, Xinyuan Chu, Yue Yuan, Suyun Qian
Summary: The purpose of this study was to explore the risk factors and develop predictive models for intravenous immunoglobulin (IVIG) resistance in children with recurrent KD. The study found that age and IVIG resistance at the first episode, as well as some laboratory variables, may be risk factors for IVIG resistance. Two predictive models for IVIG resistance with excellent performance were established.
JOURNAL OF INFLAMMATION RESEARCH
(2022)
Article
Pediatrics
Chooi San Cheah, Wendy Wei Li Lee, Siti Aisyah Suhaini, Abdullah Harith Azidin, Mohammad Shukri Khoo, Noor Akmal Shareela Ismail, Adli Ali
Summary: This study aimed to evaluate the epidemiology, clinical features, treatment, and outcomes of Kawasaki disease (KD) among pediatric patients in Hospital Canselor Tunku Muhriz, Malaysia. The study found that KD predominantly affects children under 5 years old, with a male-to-female ratio of 1.58 to 1. Various organ systems were affected, and abnormal liver parameters and incomplete KD were significantly related to IVIG resistance. The findings highlight the importance of laboratory parameters in the prognosis of KD.
FRONTIERS IN PEDIATRICS
(2023)
Article
Medicine, Research & Experimental
Nimet Oner, Elif Celikel, Zahide Ekici Tekin, Vildan Gungorer, Tuba Kurt, Pakize Nilufer Tekgoz, Muge Sezer, Cuneyt Karagol, Serkan Coskun, Melike Mehves Kaplan, Merve Cansu Polat, Banu Celikel Acar
Summary: This study evaluated the outcomes of patients with immunoglobulin A vasculitis (IgAV) involving the gastrointestinal (GI) tract who received intravenous immunoglobulin (IVIG) treatment, and compared the differences between those who responded to IVIG and those who did not. The results showed that IVIG may be considered as a treatment option for IgAV patients who are resistant to steroids and/or immunosuppressive drugs, especially in cases with multi-organ/system involvement, comorbid inflammatory diseases, or resistance to standard treatment in pediatric patients.
CLINICAL AND EXPERIMENTAL MEDICINE
(2023)
Article
Rheumatology
Hiroya Masuda, Ryusuke Ae, Taka-aki Koshimizu, Koki Kosami, Nobuko Makino, Yuri Matsubara, Teppei Sasahara, Yosikazu Nakamura
Summary: The study suggests that risk assessment for initial IVIG resistance based on serum ALT levels may only be reliable for patients with KD who visit hospitals during the early stages of illness, specifically within 1-5 days after disease onset.
CLINICAL RHEUMATOLOGY
(2022)
Editorial Material
Immunology
Varun Kumar Sharma, Jagadeesh Bayry
CELLULAR & MOLECULAR IMMUNOLOGY
(2022)
Article
Immunology
Srinivasa Reddy Bonam, Camille Chauvin, Laurine Levillayer, Mano Joseph Mathew, Anavaj Sakuntabhai, Jagadeesh Bayry
Summary: This study reports that SARS-CoV-2 induces cytokine responses, particularly IL-13, in both resting and IL-3 primed basophils. However, the expression of surface markers associated with basophil activation and PD-L1 expression on basophils are not affected by SARS-CoV-2. The results suggest that basophil cytokine responses to SARS-CoV-2 might help reduce inflammation and promote antibody responses to the virus.
FRONTIERS IN IMMUNOLOGY
(2022)
Article
Immunology
Nabarun Chandra Das, Pritha Chakraborty, Jagadeesh Bayry, Suprabhat Mukherjee
Summary: In this study, the binding abilities of eight monoclonal antibodies (mAbs) against Alpha and Delta variants of SARS-CoV-2 were assessed using computational modeling. Several mAbs were found to effectively neutralize these variants. Based on these findings, a chimeric antibody was designed to combat potential antibody-mediated neutralization escape.
FRONTIERS IN IMMUNOLOGY
(2022)
Article
Oncology
Gregory Fouquet, Constance Marie, Louison Collet, Catherine Vilpoux, Hakim Ouled-Haddou, Eric Nguyen-Khac, Jagadeesh Bayry, Mickael Naassila, Ingrid Marcq, Hicham Bouhlal
Summary: This study demonstrates the issue of acquired resistance in sorafenib treatment for advanced hepatocellular carcinoma. It shows that sorafenib-resistant cells lose expression of the tumor suppressor receptor SLAMF3, leading to increased aggressiveness and epithelial-to-mesenchymal transition. Interestingly, the overexpression of SLAMF3 can reverse the epithelial-to-mesenchymal transition and decrease metastatic potential, making it a potential therapeutic and diagnostic tool for managing sorafenib treatment.
Article
Cell Biology
Srinivasa Reddy Bonam, Camille Chauvin, Mano J. Mathew, Jagadeesh Bayry
Summary: This study identifies IFN-gamma as one of the factors that induce PD-L1 expression in human basophils and demonstrates the importance of IL-3 priming in IFN-gamma-induced PD-L1 expression.
Article
Immunology
Srinivasa Reddy Bonam, Peter Paul Platenburg, Jagadeesh Bayry
Summary: In this study, the immunopotentiating mechanism of an oil-in-water emulsion-based vaccine adjuvant called LiteVax Adjuvant (LVA) was analyzed. The researchers investigated the effect of LVA and its components on the function of dendritic cells (DC), which play a crucial role in the immune response. They found that the component CMS significantly enhanced DC activation markers, cytokine secretion, and CD4(+) T cell responses. This study identified the unique role of CMS in LVA and proposed that LVA acts as a delivery system while CMS acts as an immunostimulatory agent.
FRONTIERS IN IMMUNOLOGY
(2023)
Editorial Material
Rheumatology
Chetan Sharma, Jagadeesh Bayry
Summary: The full understanding of post-COVID-19 autoimmune diseases and their prevalence is limited. However, two large-scale studies have found a significant increase in the risk of developing various new-onset autoimmune diseases linked to SARS-CoV-2 infection.
NATURE REVIEWS RHEUMATOLOGY
(2023)
Review
Pharmacology & Pharmacy
Sruthi Vijaya Retnakumar, Camille Chauvin, Jagadeesh Bayry
Summary: T cell exhaustion is a major obstacle in mounting immune responses against chronic infections and cancers. Immune checkpoint (ICP) molecules, especially PD-1, contribute to T cell dysfunction. Blocking PD-1 can reverse T cell exhaustion and stimulate the impaired immune system. The interaction between vaccine responses and ICP therapy needs further exploration.
PHARMACOLOGY & THERAPEUTICS
(2023)
Article
Immunology
Carole El Hachem, Pierre Marschall, Pierre Hener, Anupama Karnam, Srinivasa Reddy Bonam, Pierre Meyer, Eric Flatter, Marie-Christine Birling, Jagadeesh Bayry, Mei Li
Summary: This study investigates the mechanisms of basophil recruitment to allergic skin using a mouse model of allergic contact dermatitis. It demonstrates that IL-3 produced by T cells mediates the extravasation of basophils by activating the expression of ALDH1A2, which is responsible for the production of retinoic acid. IL-3 also induces the expression of integrins involved in basophil extravasation.
FRONTIERS IN IMMUNOLOGY
(2023)
Review
Allergy
Jagadeesh Bayry, Eisha A. Ahmed, Diana Toscano-Rivero, Nicholas Vonniessen, Genevieve Genest, Casey G. Cohen, Marieme Dembele, Srini Kaveri, Bruce D. Mazer
Summary: Intravenous immunoglobulin (IVIG) plays a crucial role in the treatment of humoral immune deficiencies and inflammatory disorders. While targeted therapies are emerging, the multifunctionality of IVIG as both an effector and regulatory molecule is noteworthy. This article explores the mechanism of action of IVIG in various resistant conditions and highlights mechanistic studies that shed light on its effects on both innate and adaptive immune responses.
JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY-IN PRACTICE
(2023)
Editorial Material
Immunology
Sruthi Vijaya Retnakumar, Srinivasa Reddy Bonam, Haitao Hu, Jagadeesh Bayry
Article
Immunology
Nabarun Chandra Das, Pritha Chakraborty, Jagadeesh Bayry, Suprabhat Mukherjee
Summary: Mutation(s) in the spike protein is a major characteristic trait of newly emerged SARS-CoV-2 variants. Omicron, the latest variant, is highly transmissible and can escape host immunity. The study found that adintivimab, beludivimab, and regadanivimab are the most potent monoclonal antibodies in neutralizing Omicron variants.
Editorial Material
Cell Biology
Camille Chauvin, Sruthi Vijaya Retnakumar, Jagadeesh Bayry
Summary: Severe obesity speeds up the decline of neutralizing antibodies to COVID-19 vaccines, increasing the risk of hospitalization from breakthrough SARS-CoV-2 infections. These findings have implications for vaccination policies for SARS-CoV-2 variants and other infectious diseases like influenza in the obese population.
CELL REPORTS MEDICINE
(2023)
Article
Multidisciplinary Sciences
Camille Chauvin, Laurine Levillayer, Mathilde Roumier, Hubert Nielly, Claude Roth, Anupama Karnam, Srinivasa Reddy Bonam, Anne Bourgarit, Clement Dubost, Aurore Bousquet, Sebastien Le Burel, Raphaele Mestiri, Daminen Sene, Joris Galland, Marc Vasse, Matthieu Groh, Mathilde Le Marchand, Camille Vassord-Dang, Jean-Francois Gautier, Pham-Thi Nhan, Christian Verny, Bruno Pitaro, Cyril Planchais, Hugo Mouquet, Richard Paul, Etienne Simon-Loriere, Jagadeesh Bayry, Laurent Gilardin, Anavaj Sakuntabhai
Summary: Although tocilizumab treatment has shown efficacy in severe COVID-19 patients, its short-term use does not affect B cell sub-populations and cross-neutralization of SARS-CoV-2 variants in convalescent COVID-19 patients. The study found that SARS-CoV-2-specific IgG1 titers were dependent on disease severity rather than tocilizumab treatment. Both treated and non-treated patients had strong neutralizing activity against ancestral and several variants of SARS-CoV-2, but weaker activity against the Gamma and Omicron variants. Overall, tocilizumab therapy did not modify the robustness of cell and IgG responses to Spike antigens.
Meeting Abstract
Biophysics
Borja Rodriguez de Francisco, Isabel Valsecchi, Ariane Pille, Chi L. Pham, Vincent Dupres, Frank Lafont, Jagadesh Bayry, Vishukumar Aimanianda, Margaret Sunde, Inaki Guijarro
BIOPHYSICAL JOURNAL
(2022)
